Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
Status:
Completed
Trial end date:
2018-11-20
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and
the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with
primary ciliary dyskinesia (PCD).